Unlocking the biology of left ventricular unloading: From mechanisms to clinical translation.

The concept of left ventricular unloading is deeply embedded in the core principles of cardiac physiology, with ventricular mechanics and energetics serving as its foundation. Modern mechanical circulatory support devices vary in their loading effects. Some actively unload the LV, whereas others primarily support systemic perfusion. Notably, extracorporeal life support systems can paradoxically elevate left ventricular afterload, thereby necessitating supplementary unloading strategies. The recent DanGer-Shock trial revealed a mortality benefit associated with microaxial flow pump support in selected patients experiencing acute myocardial infarction complicated by cardiogenic shock. This finding supports the therapeutic potential of such an approach in selected patients, while highlighting the importance of considering device-specific complications and patient selection. We synthesize the hemodynamic principles and varying unloading efficiencies of different device strategies, proposing a time-dependent repair program: initial acute metabolic cytoprotection via Hippo-YAP, followed by immune reprogramming toward a reparative phenotype, and culminating in chronic structural reverse remodeling. Collectively, these insights offer a mechanism-guided framework for the application of left ventricular unloading, while highlighting emerging opportunities for biomarker-guided monitoring, device-drug synergism, and metabolic phenotyping to refine patient selection, optimize timing, and ultimately translate acute mechanical unloading from a hemodynamic support tool into a precision biological therapy.